Skip to content
Webinar Cafe
Upcoming

Kazia Therapeutics Virtual Event: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

Kazia Therapeutics · Technology / Lifescience

About this webinar

Join Kazia Therapeutics for a virtual event featuring management’s overview of NDL2, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors,…

Discussion

Sign in to join the discussion

Related webinars